Pfizer has reported positive results from a clinical trial evaluating its vaccine, ABRYSVO, in immunocompromised adults at risk of severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD).
In the trial, ABRYSVO demonstrated a favorable safety profile consistent with previous studies. Notably, a single 120 µg dose of the vaccine elicited a robust neutralizing response against both RSV subtypes in all participant groups, regardless of age.
“Immunocompromised adults face an elevated risk of severe RSV complications, but there are currently no approved vaccines for those aged 18 to 59 in the U.S.,” said Pfizer’s Senior Vice President, Dr. Annaliesa Anderson. “These data suggest that ABRYSVO has the potential to fill this unmet need.”
These findings support the growing evidence supporting ABRYSVO’s efficacy in high-risk adults. In a previous study, adults aged 18-59 with chronic conditions showed non-inferior neutralizing responses to ABRYSVO compared to those aged 60 or older.
Pfizer also announced the FDA approval of the ACT-O-VIAL® presentation of ABRYSVO, providing a new administration option alongside the existing prefilled syringe. The company plans to present these results at an upcoming scientific conference and submit them to regulatory agencies for review.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
